Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Melanoma 16Brenner Tumor 16Stomach Neoplasms 15Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 13Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Esophageal Squamous Cell Carcinoma 7Colorectal Neoplasms 7

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sinonasal Squamous Cell Carcinoma × Taxes × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡